

Taylor & Francis

OPEN ACCESS Check for updates

# Clinical outcome of early endoscopy in patients with acute upper gastrointestinal bleeding in Alexandria emergency department

Mina Montasser<sup>a</sup>, Wael Nabil Abdel Salam<sup>b</sup>, Amany Elbanna<sup>c</sup>, Dina Magdy<sup>a</sup> and Ahmed A. Sabry<sup>b</sup>

<sup>a</sup>Department of Emergency Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt; <sup>b</sup>Department of Surgery, Faculty of Medicine, Alexandria University, Alexandria, Egypt; <sup>c</sup>Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria, Egypt

#### ABSTRACT

**Background:** Upper gastrointestinal bleeding (UGIB) is a life-threatening emergency that causes considerable mortality and morbidity. The current study goal was to look at the endoscopic profile and clinical outcomes of patients with UGIB in Alexandria emergency department.

**Patients and methods:** 120 patients who had been admitted with acute UGIB were included in this study. All patients underwent upper gastrointestinal endoscopy. Outcomes that were determined included complications like re-bleeding, need for surgical intervention, mortality, hospital stay length, admission to intensive care units (ICUs), transfusion requirement, and readmission.

**Results:** The majority of patients were males (69.2%) with a mean age of (45.47  $\pm$  10.46). The most prevalent lesions causing UGIB were esophageal varices (65.8%) and (45.0%) presented with hematemesis. 51.7% were treated by band ligation. Death was reported in 5.00% and all patients who died had comorbidities, 6.7% re-bled and 50.0% of patients who re-bled were  $\geq$  60 years. 36.6% of patients had Rockall score (RS)  $\geq$  3. There was statistically significant relation between high RS and re-bleeding and mortality (p < 0.001).

**Conclusion:** We encountered that the timing of endoscopy was a good determinant of adverse outcomes in UGIB.

## 1. Introduction

Acute upper gastrointestinal bleeding (UGIB) is a prevalent emergency that necessitates hospitalizaquick tion, assessment, and management. Hematemesis and/or melena are the most common presenting symptoms. UGIB is more common in elderly men [1]. Older age, Helicobacter pylori, medication, smoking, and a history of chronic liver disease are all risk factors. Patients at the highest risk should be identified using risk scores [2]. The causes of UGIB had been divided into two categories: variceal bleeding and non variceal bleeding [3]. The Rockall score (RS) Table 1 [4] and the Glasgow-Blatchford score (GBS) are the commonly used scores [5]. Endoscopy should be performed within 24 hours of presentation [6].

Early upper gastrointestinal endoscopy (UGIE) is linked to lower death rates and decreased length of hospital stay [7]. The purpose of this study was to assess the role of early UGIE and to determine the impact of early endoscopy on clinical outcomes in patients presenting with acute UGIB in emergency department (ED).

# 2. Patients and methods

This prospective study was conducted on 120 patients more than 18 years who were admitted to ED of Alexandria Main University Hospital with nontraumatic acute UGIB who underwent UGIE within 24 hours of admission. Every patient provided written and informed consent. Before beginning, we obtained approval from our institute's ethical committee. Patients were excluded if they did not give written consent, aged ≤18 years, pregnant, on anticoagulant medication, if UGIE was performed more than 24 hours from admission, and who were not stabilized after initial resuscitation. All patients were subjected to history taking and clinical evaluation. Laboratory tests were done with assessment of risk stratification by RS [8]. UGIE was performed and endoscopic findings were recorded. Figure 2 The primary outcomes as the mortality rate, re-breeding and the need for surgical or radiologic intervention and the secondary outcomes as hospital length of stay, admission to ICUs, transfusion requirement and re-admission within 1 month were reported. Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk,

**CONTACT** Dina Magdy Alexandria University, Alexandria, Egypt

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

#### **ARTICLE HISTORY**

Received 20 August 2023 Revised 30 September 2023 Accepted 9 October 2023

#### KEYWORDS

Endoscopy; re-bleeding; Rockall score; upper gastrointestinal bleeding; varices

<sup>© 2023</sup> The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

| Risk indicator        | Score   |   |  |
|-----------------------|---|---|--|
| Age                   | <60   | 0 |  |
| 2                     | 60–79   | 1 |  |
|                       | >80   | 2 |  |
| Shock index           | No shock  | 0 |  |
|                       | Pulse >100, SBP > 100                           | 1 |  |
|                       | SBP <100  | 2 |  |
| Comorbidity           | No major comorbidity                            | 0 |  |
|                       | Major comorbidity                               | 2 |  |
|                       | Renal failure, liver failure, metastatic cancer | 3 |  |
| Endoscopic diagnosis  | Mallory-weiss lesion                            | 0 |  |
|                       | All other diagnosis                             | 1 |  |
|                       | GI malignancy                                   | 2 |  |
| Proof of hemorrhaging | None  | 0 |  |
|                       | Blood, adherent clot, spurting vessel           | 2 |  |

Table 1. The Rockall score.

NY: IBM Corp). Categorical data were represented as numbers and percentages. **Chi-square test** was applied to compare between two groups. Alternatively, **Fisher Exact or Monte Carlo correction** test was applied when more than 20% of the cells have expected count less than 5. For continuous data, they were tested for normality by the **Kolmogorov-Smirnov**. Quantitative data were expressed as range (minimum and maximum), mean, standard deviation and median for normally distributed quantitative variables **Student t-test** was used to compare two groups. On the other hand for not normally distributed quantitative variables **Mann Whitney test** was used to compare two groups. Significance of the obtained results was judged at the 5% level.

# 3. Results

In this study, the mean age was  $45.5 \pm 10.5$  years with a male to female ratio 2.2:1 (M: 83, F: 37). Table 2

The most common presenting symptom was hematemesis (48.4%), and most common lesions causing UGIB were esophageal varices (65.8%), with a mean RS of 2.83  $\pm$  1.59 (Figure 1).

In this study, 62 patients were managed by band ligation (51.7%), 20 patients were managed by

| Table 2. Distribution of the studied cases according to different parameter | rs |
|---|----|
| ( <i>n</i> = 120).  |    |

|                            | No. (%)         |
|----------------------------|-----------------|
| Gender                     |                 |
| Male                       | 83 (69.2%)      |
| Female                     | 37 (30.8%)      |
| Male/Female ratio          | 2.2:1%          |
| Age (years)                |                 |
| <20                        | 0 (0.0%)        |
| 20–39                      | 44 (36.7%)      |
| 40–59                      | 66 (55.0%)      |
| ≥60                        | 10 (8.3%)       |
| Mean $\pm$ SD.             | $45.5 \pm 10.5$ |
| Median (Min. – Max.)       | 47 (24–66)      |
| Comorbidities              |                 |
| No                         | 39 (32.5%)      |
| Yes                        | 81 (67.5%)      |
| Chronic liver disease      | 66 (55.0%)      |
| Chronic viral hepatitis    | 25 (20.8%)      |
| Peptic ulcer disease       | 16 (13.3%)      |
| DM                         | 16 (13.3%)      |
| HTN                        | 9 (7.5%)        |
| IHD                        | 12 (10.0%)      |
| CKD                        | 8 (6.7%)        |
| Risk factors               |                 |
| NSAIDs                     | 20 (16.7%)      |
| Steroid                    | 14 (11.7%)      |
| Smoking                    | 33 (27.5%)      |
| Risk score                 |                 |
| Low risk (<3)              | 76 (63.3%)      |
| Moderate risk (3–5)        | 37 (30.8%)      |
| High risk (>5)             | 7 (5.8%)        |
| Mean $\pm$ SD.             | $2.83 \pm 1.59$ |
| Median (Min. – Max.)       | 2 (1-11)        |
| Endoscopic treatment       | (54 70()        |
| Band ligation              | 62 (51.7%)      |
| Adrenaline Injection       | 3 (2.5%)        |
| Adrenaline + Band ligation | 11 (9.2%)       |
| Scierotnerapy              | 20 (16.7%)      |
| Uthers                     | 24 (20.0%)      |



**Figure 1.** Distribution of the studied cases according to endoscopic profile (n = 120).

sclerotherapy (16.7%), 24 patients were managed by other methods (glue injection, hemospray) (20.0%), 11 patients were managed by Adrenaline injection+ Band ligation (9.2%), and 3 patients were managed by adrenaline injection (2.5%) (Table 2 and Figure 2).

In this study, 8 patients re-bled after endoscopy (6.7%), while 6 patients died (5.0%), 2 patients need surgery after endoscopy (1.7%), 4 patients were re-admitted to the hospital within 1 month (3.3%), and 18 patients received blood transfusion (15.0%) with a mean of  $3.56 \pm 1.10$  units of blood. The mean of hospital stay was  $2.05 \pm 1.03$  days, with a mean of ICU stay of  $2.0 \pm 0.73$  days. Table 3.

There was statistically significant association between re-bleeding and comorbidities as chronic viral hepatitis, DM, HTN, IHD, and CKD

There was statistically significant association between re-bleeding and low Hb, low platelet count, high INR, prolonged PT, prolonged PTT, abnormal LFT, elevated RFT, high serum sodium level, high RBG, and high RS.

There was statistically significant association between mortality and increasing age, comorbidities, low Hb, low platelets count, high WBCs count, elevated INR, prolonged PT, prolonged PTT, abnormal LFT, elevated RFT, high serum sodium level, high RBG, and high RS (Table 4). After assessing multivariate analysis



| cases according to outcome ( $n = 120$ ). |                 |  |  |  |  |
|---|-----------------|--|--|--|--|
| Outcome                                   | No. (%)         |  |  |  |  |
| Re-bleeding                               | 8 (6.7%)        |  |  |  |  |
| Surgery                                   | 2 (1.7%)        |  |  |  |  |
| Mortality                                 | 6 (5.0%)        |  |  |  |  |
| Hospital stay (days)                      |                 |  |  |  |  |
| Mean $\pm$ SD.                            | $2.05 \pm 1.03$ |  |  |  |  |
| Median (Min. – Max.)                      | 2 (1–7)         |  |  |  |  |
| ICU stay (days)                           | 16 (13.3%)      |  |  |  |  |
| Mean $\pm$ SD.                            | $2 \pm 0.73$    |  |  |  |  |
| Median (Min. – Max.)                      | 2 (1–3)         |  |  |  |  |
| Blood transfusion                         | 18 (15.0%)      |  |  |  |  |
| Mean $\pm$ SD.                            | 3.56 ± 1.10     |  |  |  |  |
| Median (Min. – Max.)                      | 4 (2–6)         |  |  |  |  |
| Re-admission                              | 4 (3.3%)        |  |  |  |  |

Table 3. Distribution of the studied

for the most important predictors, it was found that viral hepatitis was significant after controlling for age, DM, IHD [OR = 9.184 (1.277-66.033), P = 0.028 for rebleeding] and [OR = 21.084 (1.169–380.185), P = 0.039 for mortality].

#### 4. Discussion

Majority of the patients (69.2%) were males, in a study by Kumar et al; 72% of patients were males [9]. The mean age in **Dewan et al's** study was (48.76 + 17.19) [10]. In Alexandrino et al.'s study the mean age was 67 years [11].

Regarding the presenting symptoms, our results agreed with Gado et al; hematemesis was much commoner than melena [12]. Regarding comorbidities, Moledina et al. found that 62.4% of patients had comorbidities [13]. Results of the present study agreed with a previous study, they found that (54%) of patients had history of chronic liver disease [9]. Our results disagreed with another study by Minakari et al; peptic ulcer was detected as the main reason for UGIB in 42.4% of patients [14]. Regarding the risk factors, a study by Gokaket et al. noted that 19% of patients reported the intake of NSAIDs, aspirins and smoking in 16% [15]. In the current study 30.8% of patients had moderate risk RS (3-5). Rajan et al.'s results found that 51.2% of the patients had a moderate risk RS of (3-4) [16].

In the current study, the majority of patients had esophageal varices and nearly half of patients were treated by band ligation. In a study by Hafez et al. 57% had esophageal varices [17]. In the study by Karki et al. Endotherapy was required in 50.59% of cases, which included esophageal band ligation in 47.06% cases [18]. Regarding the patients' outcomes in the current study, similar results were reported by Alexandrino et al; death was reported in 6.9% of patients, rebleeding in 14.7%, while need for surgery in 5.9%, and ICU admission in 5.9% [11].

Our results showed statistically significant association between re-bleeding and low Hb, low platelet count, high INR, prolonged PT, PTT and re-bleeding. Ramos et al. found that an increased INR > 2 was a predictor of recurrent bleeding [19].

Our results showed statistically significant association between elevated liver enzymes, elevated RFT and re-bleeding. Low albumin level and high bilirubin were risk factors for early re-bleeding after esophageal variceal ligation [20]. Low albumin level was associated with increased risk of rebleeding [21]. Jiménez et al. found that high creatinine level was independent risk factor for rebleeding [22]. While elevated creatinine was not significantly associated with re-bleeding in study by Parveen et al [23]. In this study, all the patients who re-bled had high RS. An association was found between high clinical RS and re-bleeding in patients with non-variceal UGIB in Frías-Ordoñez et al. [24] Also, there was a significant association between high RS and re-bleeding in Wang et al; study [25]. In this study, the majority of dead patients were males,  $\geq 60$  years. According to study by Minakari et al; older patients had higher mortality rate [14].

Results showed that all patients who died had comorbidities. These results agreed with a study by Corzo et al; cirrhosis was related to increased mortality rate [26]. We noted statistically significant association between elevated INR, prolonged PT, PTT and mortality. Predictors of mortality in other study by **Ramos et al.** were INR > 2, aPTT >38 seconds [19]. In this study, all the patients who died had high RS, these agreed with research by Corzo et al; RS greater than 4 was related to increased mortality rate [26].

#### **Table 4.** Relation between mortality and different parameters (n = 120).

|                         | Mortality         |                  |                          |                           |
|-------------------------|-------------------|------------------|--------------------------|---------------------------|
|                         | Alive             | Dead             |                          |                           |
|                         | ( <i>n</i> = 114) | ( <i>n</i> = 6)  | Test of Sig.             | р                         |
| Gender                  |                   |                  |                          |                           |
| Male                    | 79 (69.3%)        | 4 (66.7%)        | $\chi^2 = 0.019$         | <sup>FE</sup> p= 1.000    |
| Female                  | 35 (30.7%)        | 2 (33.3%)        |                          |                           |
| Age (years)             |                   |                  |                          |                           |
| <20                     | 0 (0.0%)          | 0 (0.0%)         | $\chi^2 = 14.325^*$      | <sup>мс</sup> р= 0.001*   |
| 20–39                   | 43 (37.7%)        | 1 (16.7%)        |                          |                           |
| 40–59                   | 65 (57.0%)        | 1 (16.7%)        |                          |                           |
| ≥60                     | 6 (5.3%)          | 4 (66.7%)        |                          |                           |
| Mean $\pm$ SD.          | 45 ± 10.2         | 55.2 ± 11.5      | t= 2.376*                | 0.019*                    |
| Comorbidities           |                   |                  |                          |                           |
| No                      | 39 (34.2%)        | 0 (0.0%)         | 3.041                    | $F^{F}p = 0.175$          |
| Yes                     | 75 (65.8%)        | 6 (100.0%)       |                          |                           |
| Chronic liver disease   | 61 (53.5%)        | 5 (83.3%)        | 2.049                    | p = 0.221                 |
| Chronic viral hepatitis | 20 (17.5%)        | 5 (83.3%)        | 14.958*                  | $p = 0.001^{*}$           |
| Peptic ulcer disease    | 14 (12.3%)        | 2 (33.3%)        | 2.186                    | p = 0.182                 |
| DM                      | 12 (10.5%)        | 4 (66.7%)        | 15.547*                  | $p = 0.003^{*}$           |
| HTN                     | 6 (5.3%)          | 3 (50.0%)        | 16.444*                  | $p = 0.005^{*}$           |
| IHD                     | 7 (6.1%)          | 5 (83.3%)        | 37.739*                  | <sup>FE</sup> p <0.001*   |
| CKD                     | 2 (1.8%)          | 6 (100.0%)       | 88.421*                  | <sup>re</sup> p <0.001*   |
| Hb (g/dl)               |                   |                  |                          |                           |
| Mean $\pm$ SD.          | 9.37 ± 0.63       | $6.17 \pm 0.26$  | t = 12.362*              | <0.001*                   |
| Platelet (cell/mcl)     | /                 |                  |                          |                           |
| Median (Min. – Max.)    | 200 (130–400)     | 125 (100–150)    |                          |                           |
| WBCs (*103/mm3)         |                   |                  |                          |                           |
| Median (Min. – Max.)    | 6.0 (4.0–9.0)     | 12.0 (4.0–15.0)  |                          |                           |
| INK<br>Madian (Min May) | 1 10 (0 00 1 20)  | 1 20 (1 20 1 40) |                          |                           |
| BT (second)             | 1.10 (0.80–1.30)  | 1.30 (1.20–1.40) |                          |                           |
| Modian (Min Max)        | 14 (11 15)        | 16 (16 16)       |                          |                           |
| PTT (second)            | 14 (11–13)        | 10 (10-10)       |                          |                           |
| Median (Min _ Max)      | 36 5 (25-45)      | 45 (40-45 0)     |                          |                           |
|                         | 50.5 (25-45)      |                  |                          |                           |
| Median (Min – Max)      | 43 5 (15-87)      | 82 5 (25-88)     |                          |                           |
| ALT (U/L)               | 13.3 (13 07)      | 02.13 (23 00)    |                          |                           |
| Median (Min. – Max.)    | 55 (19–90)        | 90 (35–99)       |                          |                           |
| Bilirubin (ma/dl)       |                   |                  |                          |                           |
| Median (Min. – Max.)    | 0.80 (0.20-4)     | 3 (3–4)          |                          |                           |
| Albumin (g/dl)          |                   | . ,              |                          |                           |
| Median (Min. – Max.)    | 4.10 (1.40-5.20)  | 1.30 (1–1.60)    |                          |                           |
| Urea (mg/dl)            |                   |                  |                          |                           |
| Median (Min. – Max.)    | 40 (20–60)        | 80 (60–90)       |                          |                           |
| Creatinine (mg/dl)      |                   |                  |                          |                           |
| Median (Min. – Max.)    | 0.80 (0.70-3)     | 3 (2–4)          |                          |                           |
| Na+ (meq/l)             |                   |                  |                          |                           |
| Mean $\pm$ SD.          | $138.9 \pm 7.41$  | 148.7 ± 9.42     | t = 3.121*               | 0.002*                    |
| K+ (meq/l)              |                   |                  |                          |                           |
| Median (Min. – Max.)    | 4.50 (3–6)        | 4.25 (3–6)       |                          |                           |
| RBG (mg/dl)             |                   | /                |                          |                           |
| Median (Min. – Max.)    | 133 (80–300)      | 275 (138–350)    |                          |                           |
| Rockall                 |                   | a (a)            | 2                        | МС                        |
| Low risk (<3)           | 76 (66.7%)        | 0 (0.0%)         | χ <sup>2</sup> = 37.464* | <sup>,,,,</sup> p <0.001* |
| Moderate risk(3–5)      | 37 (32.5%)        | 0 (0.0%)         |                          |                           |
| High risk (>5)          | 1 (0.9%)          | 6 (100.0%)       |                          |                           |
| Median (Min. – Max.)    | 2 (1–6)           | 8 (/-11)         |                          |                           |

SD: Standard deviation, t: Student t-test, U: Mann Whitney test,  $\chi^2$ : Chi square test MC: Monte Carlo.

p: *p* value for Relation between mortality and different parameters. \*: Statistically significant at  $p \le 0.05$ .

# 5. Conclusion

In patients with acute UGIB, endoscopy performed within 24 hours was associated with improved clinical outcome in terms of in-hospital mortality, rebleeding, transfusion requirements and need for surgery. Predictors that were significant for mortality included older age, comorbidities as (chronic viral hepatitis, DM, HTN, IHD, CKD), low Hb level, low platelet count, elevated INR, abnormal liver blood tests, renal impairment, hypernatremia, hyperglycemia and high RS.

## **Disclosure statement**

No potential conflict of interest was reported by the author(s).

#### References

- [1] Nukala K, Srinivasan VR, Sagar RV. Clinical presentation of cases with upper gastro - intestinal bleeding. J Assoc Physicians India. 2022;70(4):11-12.
- [2] Costable NJ, Greenwald DA. Upper gastrointestinal bleeding. Clin Geriatr Med. 2021;37(1):155-172. doi: 10.1016/j.cger.2020.09.001

- [3] Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. BMJ. 2019;364:I536. doi: 10. 1136/bmj.I536
- [4] Rockall TA, Logan RF, Devlin HB, et al. Variation in outcome after acute upper gastrointestinal haemorrhage. National Audit Acute Upper Gastrointestinal Haemorrhage Lancet. 1995;346 (8971):346–350. doi: 10.1016/S0140-6736(95)92227-X
- [5] Costa-Moreira P, Macedo G. Risk stratification in upper gastrointestinal bleeding: a measure of safety and efficiency in emergency care. GE Port J Gastroenterol. 2021;28(4):231–233. doi: 10.1159/000512091
- [6] Laine L. Timing of endoscopy in patients hospitalized with upper gastrointestinal bleeding. N Engl J Med. 2020;382(14):1361–1363. doi: 10.1056/NEJMe2002121
- [7] Cho SH, Lee YS, Kim YJ, et al. Outcomes and role of urgent endoscopy in high-risk patients with acute nonvariceal gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2018;16(3):370–377. doi: 10. 1016/j.cgh.2017.06.029
- [8] Chen L, Zheng H, Wang S. Prediction model of emergency mortality risk in patients with acute upper gastrointestinal bleeding: a retrospective study. Peer J. 2021;9:e11656. doi: 10.7717/peerj.11656
- [9] Kumar A, Kasturi U, Singh A, et al. Endoscopic profile and clinical outcome of patients presenting with upper gastrointestinal bleeding. Int J Adv Med. 2020;7(9):1355–1360. doi: 10.18203/2349-3933. ijam20203598
- [10] Dewan KR, Patowary BS, Bhattarai S. A study of clinical and endoscopic profile of acute upper, gastrointestinal bleeding. Kathmandu Univ Med J (KUMJ). 2014;12 (45):21–25. doi: 10.3126/kumj.v12i1.13628
- [11] Alexandrino G, Domingues TD, Carvalho R, et al. Endoscopy timing in patients with acute upper gastrointestinal bleeding. Clin Endosc. 2019;52(1):47–52. doi: 10.5946/ce.2018.093
- [12] Gado AS, Ebeid BA, Abdelmohsen AM, et al. Clinical outcome of acute upper gastrointestinal hemorrhage among patients admitted to a government hospital in Egypt. Saudi J Gastroenterol. 2012;18(1):34–39. doi: 10. 4103/1319-3767.91737
- [13] Moledina SM, Komba E. Risk factors for mortality among patients admitted with upper gastrointestinal bleeding at a tertiary hospital: a prospective cohort study. BMC Gastroenterol. 2017;17(1):165. doi: 10. 1186/s12876-017-0712-8
- [14] Minakari M, Badihian S, Jalalpour P, et al. Etiology and outcome in patients with upper gastrointestinal bleeding: study on 4747 patients in the central region of Iran. J Gastroenterol Hepatol. 2017;32(4):789–796. doi: 10.1111/jgh.13617
- [15] Gokak VP, Hajare S, Patil A, et al. Clinical profile of patients presenting with upper gastrointestinal bleed

in a tertiary care hospital from South India. Int J Sci Res. 2018;8:802–805.

- [16] Rajan SS, Sawe HR, Iyullu AJ, et al. Profile and outcome of patients with upper gastrointestinal bleeding presenting to urban emergency departments of tertiary hospitals in Tanzania. BMC Gastroenterol. 2019;19 (1):212. doi: 10.1186/s12876-019-1131-9
- [17] Hafez MZE, Kassem SA, Abd-Allah MAH. Assessment of the causes and outcomes of upper gastrointestinal tract bleeding patients in Aswan university hospital. Egypt J Hosp Med. 2019;74(6):1359–1364. doi: 10. 21608/ejhm.2019.26700
- [18] Karki B, Sherpa TW, Aryal E, et al. Upper gastrointestinal bleeding among patients admitted in department of emergency in a tertiary care centre: a descriptive cross-sectional study. JNMA J Nepal Med Assoc. 2022;60(248):360–363. doi: 10.31729/jnma.7409
- [19] Ramos GP, Binder M, Hampel P, et al. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointest Endosc. 2018;88(1):55–61. doi: 10.1016/j.gie.2018.01.028
- [20] Zhou JN, Wei Z, Sun ZQ. Risk factors for early rebleeding after esophageal variceal ligation in patients with liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 2016;24(7):486–492. doi: 10.3760/cma.j.issn.1007-3418.2016.07.002
- [21] Bunchorntavakul C, Yodket Y, Singhasena N. Clinical characteristics, treatment outcomes and risk assessment of patients with acute upper gastrointestinal bleeding in Rajavithi hospital, Thailand. J Med Assoc Thai. 2017;100 Suppl 1:S104–15.
- [22] Jiménez Rosales R, Martínez-Cara JG, Vadillo-Calles F, et al. Analysis of rebleeding in cases of an upper gastrointestinal bleed in a single center series. Rev Esp Enferm Dig. 2019;111(3):189–192. doi: 10.17235/ reed.2018.5702/2018
- [23] Parveen S, Shah AH, Zargar SA, et al. Predictors of rebleeding in non-variceal upper gastrointestinal bleeding of Peptic ulcer etiology in Kashmiri Population. Cureus. 2023;15(1):e33953. doi: 10.7759/cureus.33953
- [24] Frías-Ordoñez JS, Arjona-Granados DA, Urrego-Díaz JA, et al. Validation of the rockall score in upper gastrointestinal tract bleeding in a colombian tertiary hospital. Arq Gastroenterol. 2022;59(1):80–88. doi: 10. 1590/s0004-2803.202200001-15
- [25] Wang CY, Qin J, Wang J, et al. Rockall score in predicting outcomes of elderly patients with acute upper gastrointestinal bleeding. World J Gastroenterol. 2013;19(22):3466–3472. doi: 10.3748/wjg.v19.i22.3466
- [26] Corzo Maldonado MA, Guzmán Rojas P, Bravo Paredes EA, et al. Risk factors associated to mortality by upper GI bleeding in patients from a public hospital. A case control study. Rev Gastroenterol Peru. 2013;33(3):223–229.